Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know.

Padhani, Anwar R;Tunariu, Nina;Perez-Lopez, Raquel;Tombal, Bertrand;Lecouvet, Frédéric
(2024) European Radiology : journal of the European Congress of Radiology — Vol. 34, n° 12, p. 7564-7566 (2024)

Files

2024_Padhani_Eur_Radiol.pdf
  • Restricted Access
  • Adobe PDF
  • 330.25 KB
Request a copy

Details

Authors
Abstract
Serum prostate-specific antigen (PSA) is a recognised biomarker for monitoring therapy response in metastatic hormone-sensitive prostate cancer (mHSPC), with clinical practice guideline recommendations. The modern treatment of mHSPC relies on the combination of androgen deprivation therapy and androgen receptor (AR)-targeted agents (ARTA), with/without chemotherapy and prostate-pelvic radiotherapy. Patients achieving a deep PSA response to intensified treatment for mHSPC have improved overall survival. However, treatment-emergent disease variants develop under intense AR inhibition that do not secrete PSA or are oligo-secretory, impairing the detection of disease progression. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Padhani, A. R., Tunariu, N., Perez-Lopez, R., Tombal, B., & Lecouvet, F. (2024). Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know. European Radiology : journal of the European Congress of Radiology, 34(12), 7564-7566. https://doi.org/10.1007/s00330-024-10864-8 (Original work published 2024)